SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series

被引：13
|
作者：
Zampieri, Mattia [1 ,2 ]
Argiro, Alessia [1 ,2 ]
Allinovi, Marco [1 ]
Perfetto, Federico [1 ,3 ]
Cappelli, Francesco [1 ,4 ]
机构：
[1] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Largo Brambilla 3, I-50134 Florence, Italy
[2] Careggi Univ Hosp, Cardiomyopathy Unit, Florence, Italy
[3] Careggi Univ Hosp, IV Internal Med Div, Florence, Italy
[4] Careggi Univ Hosp, Div Intervent Struct Cardiol, Cardiothoracovasc Dept, Florence, Italy
来源：
INTERNAL AND EMERGENCY MEDICINE | 2022年 / 17卷 / 04期
关键词：
Amyloidosis; SGLT2i; Heart failure; Diabetes; Empaglifozin; Dapagliflozin; Canagliflozin;
D O I：
10.1007/s11739-022-02944-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1243 / 1245
页数：3
相关论文
共 50 条
  • [31] ELIGIBILITY AND PROTEOMIC CLUSTER PROFILES OF REAL-WORLD PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION IN LANDMARK SGLT2-INHIBITOR TRIALS
    Weerts, Jerremy
    Mourmans, Sanne
    Borras, Eva
    Barandiaran, Arantxa
    Sikking, Maurits
    van Wijk, Sandra
    Rocca, Hans-Peter Brunner-La
    Achten, Anouk
    Rietzschel, Ernst R.
    Knackstedt, Christian
    Zamani, Payman
    Fischer, Aryeh
    Zhao, Lei
    Maya, Juan
    Chirinos, Julio A.
    Egea, Oriol Iborra
    Bayes-Genis, Antoni
    Van Empel, Vanessa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 322 - 322
  • [32] Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
    Brunton, Stephen
    Rozjabek, Heather M.
    Pilon, Dominic
    Lafeuille, Marie-Helene
    Kamstra, Rhiannon
    Wynant, Willy
    Bookhart, Brahim K.
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) : 1607 - 1614
  • [33] Risk of diabetic microvascular complications, heart failure, hospitalisation and all-cause mortality with SGLT2i and GLP1-ra in type 2 diabetes: a real-world data study
    Eleftheriadou, A.
    Riley, D.
    Austin, P.
    Hernandez, G.
    Alam, U.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S74 - S74
  • [34] Association of Changes in Heart Failure Treatment With Patients' Health Status Real-World Evidence From CHAMP-HF
    Thomas, Merrill
    Khariton, Yevgeniy
    Fonarow, Gregg C.
    Arnold, Suzanne, V
    Hill, Larry
    Nassif, Michael E.
    Sharma, Puza P.
    Butler, Javed
    Thomas, Laine
    Duffy, Carol, I
    DeVore, Adam D.
    Hernandez, Adrian
    Albert, Nancy M.
    Patterson, J. Herbert
    Williams, Fredonia B.
    McCague, Kevin
    Spertus, John A.
    JACC-HEART FAILURE, 2019, 7 (07) : 615 - 625
  • [35] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
    Budde, L. Elizabeth
    Sehn, Laurie H.
    Matasar, Matthew J.
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Wei, Michael C.
    Yin, Shen
    Doral, Michelle Y.
    Li, Chi-Chung
    Huang, Huang
    Negricea, Raluca
    Penuel, Elicia
    O'Hear, Carol
    Bartlett, Nancy L.
    BLOOD, 2021, 138
  • [36] Disparities in SGLT2i utilization among heart failure patients with different ejection fraction in China: findings from chinese cardiovascular association database-heart failure center registry
    Zhang, Q.
    Fan, F.
    Yang, F.
    Zhou, Z.
    Jia, J.
    Jiang, J.
    Gao, Y.
    Liao, Y.
    Li, W.
    Dong, Y.
    Li, X.
    Zhou, J.
    Gong, Y.
    Yang, J.
    Huo, Y.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [37] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received.2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
    Budde, Elizabeth L.
    Sehn, Laurie H.
    Matasar, Matthew
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Wei, Michael C.
    Yin, Shen
    Doral, Michelle Y.
    Li, Chi-Chung
    Huang, Huang
    Negricea, Raluca
    Penuel, Elicia
    O'Hear, Carol
    Bartlett, Nancy L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S387
  • [38] Rates of Acute Kidney Injury or Discontinuation After SGLT2 Inhibitor Initiation in a Real-World Cohort of Patients With Heart Failure With Reduced Ejection Fraction
    Martinez, Bryan Perez
    Adie, Sarah
    Konerman, Matthew C.
    CIRCULATION, 2022, 146
  • [39] Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience
    Tabella, Erika
    Correale, Michele
    Alcidi, Gianmarco
    Pugliese, Rosanna
    Ioannoni, Sara
    Romano, Matteo
    Palmieri, Gianpaolo
    Di Biase, Matteo
    Brunetti, Natale Daniele
    Iacoviello, Massimo
    CLINICS AND PRACTICE, 2023, 13 (05) : 1015 - 1024
  • [40] PERIOPERATIVE UTILIZATION OF GUIDELINE DIRECTED THERAPY IN HEART FAILURE PATIENTS UNDERGOING NON-CARDIAC SURGERY: DATA FROM A REAL-WORLD COHORT
    Elharram, Malik
    Wang, Xiaoming
    Gouda, Pishoy
    Graham, Michelle
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 548 - 548
12345